Blistering Lesions Associated With Loncastuximab Tesirine

JAMA Dermatol. 2022 Jul 1;158(7):831-832. doi: 10.1001/jamadermatol.2022.1389.

Authors

Shadai Gociman¹, Kelsey Baron², Boyu Hu³, Jamie Zussman¹, Lauren M Madigan¹

Affiliations

¹ Department of Dermatology, University of Utah School of Medicine, Salt Lake City.
² Division of Internal Medicine, University of Utah School of Medicine, Salt Lake City.
³ Division of Hematology/Hematologic Malignancies, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.

PMID: 35583892
DOI: 10.1001/jamadermatol.2022.1389

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Benzodiazepines* / adverse effects
Blister
Humans

Substances

Antibodies, Monoclonal, Humanized
Benzodiazepines
loncastuximab tesirine